Current/ Expected Orderbook/ Pending Orders?

The transcript does not specifically mention the current or expected order book or pending orders for Themis Medicare Limited. However, it highlights a strong momentum in the hospital segment with 20% growth in Q2 FY’24 and expectations of even higher growth ahead. The company has completed de-bottlenecking to meet demand, implying a readiness to fulfill existing and future orders. Multiple new product launches, including Remithem (Remifentanil) and others, are expected to boost hospital business growth. Investments in expanding the hospital team and marketing efforts signal increasing capacit

Any current/future new fundraising through debt or equity?

There is no specific mention of any current or planned new fundraising through debt or equity in the call transcript. The company stated that they have not planned any capital expenditure (capex) for capacity expansion in the next few years, indicating no immediate need for fundraising for expansion. The API business is being transferred to a wholly-owned subsidiary to focus and streamline growth; no fundraising related to this is indicated. The company emphasized reliance on contract manufacturing to meet demand instead of investing in new manufacturing capacity. They are focusing on improvin

Any current/future capex/capital investment/strategic investment?

No significant planned capex for capacity expansion over the next few years; current production can be met through contract manufacturing facilities. Investment focus is on increasing productivity and marketing efforts rather than expanding manpower or fixed capacity. The company has set up a small R&D unit in Gujarat (Baroda) to work on certain molecules not permitted in existing facilities; this is not a manufacturing unit. Strategic investment is focused on expanding product offerings in hospital business, leveraging existing distribution networks. Capital allocation is more towards varied

Future growth expectations in sales/revenue/volumes?

The hospital segment is expected to see significantly higher growth in the second half of the year compared to the first half, driven by de-bottlenecking and improved supply capabilities. New product launches, such as Remithem, are anticipated to boost sales and expand market presence, especially in hospitals. The domestic hospital and trade (branded) businesses contributed notably to recent growth, with trade domestic business growing 35-40%. Growth is expected to sustain and improve in the domestic market as the company leverages its established distribution network and expands product offer

Future growth expectations in earnings/operating earnings/profits/EPS?

Hospital segment expected to experience significantly higher growth in the second half of FY ’24 due to resolved supply constraints and new product launches (e.g., Remithem). Strong focus on increasing hospital product basket and doctor touchpoints to drive revenue without significantly increasing fixed costs. EBITDA margin pressure due to raw material price increases (API costs) and manpower additions in hospital business; improvements expected as new API manufacturing routes are adopted and operational productivity rises. Long-term strategy includes investing more in marketing, which may tem

Themis MedicareQ2 FY24Pharmaceuticals & Biotechnology

Themis Medicare Q2 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹99.73Market Cap: ₹919 CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 2

Margin

Category 1

Fundraise

N/A

Order

N/A

Capex

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 2

The hospital segment is expected to see significantly higher growth in the second half of the year compared to the first half, driven by de-bottlenecking and improved supply capabilities.
New product launches, such as Remithem, are anticipated to boost sales and expand market presence, especially in hospitals.
The domestic hospital and trade (branded) businesses contributed notably to recent growth, with trade domestic business growing 35-40%.
Growth is expected to sustain and improve in the domestic market as the company leverages its established distribution network and expands product offerings.
Marketing investments aim to increase doctor touchpoints and product portfolio in hospitals without increasing fixed costs, focusing on productivity over headcount growth.
The company foresees no major capacity expansion capex soon, relying on contract manufacturing to meet rising demand.
Long-term strategy includes expanding into women’s healthcare and other hospital specialties for diversified growth.

Margin guidance

Category 1

Hospital segment expected to experience significantly higher growth in the second half of FY ’24 due to resolved supply constraints and new product launches (e.g., Remithem).
Strong focus on increasing hospital product basket and doctor touchpoints to drive revenue without significantly increasing fixed costs.
EBITDA margin pressure due to raw material price increases (API costs) and manpower additions in hospital business; improvements expected as new API manufacturing routes are adopted and operational productivity rises.
Long-term strategy includes investing more in marketing, which may temporarily depress margins but should drive top-line growth.
API business transfer to a subsidiary to streamline focus and growth expected to benefit overall financials.
EPS showed growth with H1 FY ’24 EPS at INR32.07 and quarter EPS at INR12.30, expected to improve with margin recovery and revenue growth.

See what Themis Medicare management said on margin guidance — free account, 30 seconds.

Fundraise plans

There is no specific mention of any current or planned new fundraising through debt or equity in the call transcript.
The company stated that they have not planned any capital expenditure (capex) for capacity expansion in the next few years, indicating no immediate need for fundraising for expansion.
The API business is being transferred to a wholly-owned subsidiary to focus and streamline growth; no fundraising related to this is indicated.
The company emphasized reliance on contract manufacturing to meet demand instead of investing in new manufacturing capacity.
They are focusing on improving productivity and marketing within existing resources.
No explicit plans for issuing new equity or raising debt were discussed during this period.

Order book

The transcript does not specifically mention the current or expected order book or pending orders for Themis Medicare Limited.
However, it highlights a strong momentum in the hospital segment with 20% growth in Q2 FY’24 and expectations of even higher growth ahead.
The company has completed de-bottlenecking to meet demand, implying a readiness to fulfill existing and future orders.
Multiple new product launches, including Remithem (Remifentanil) and others, are expected to boost hospital business growth.
Investments in expanding the hospital team and marketing efforts signal increasing capacity to handle more orders.
Contract manufacturing partnerships indicate preparation to meet rising demand without capex expansion.
Overall, while exact orderbook numbers aren't given, the company is positioned for a robust increase in order flow and execution going forward.

See what Themis Medicare management said on order book — free account, 30 seconds.

Capex plans

No significant planned capex for capacity expansion over the next few years; current production can be met through contract manufacturing facilities.
Investment focus is on increasing productivity and marketing efforts rather than expanding manpower or fixed capacity.
The company has set up a small R&D unit in Gujarat (Baroda) to work on certain molecules not permitted in existing facilities; this is not a manufacturing unit.
Strategic investment is focused on expanding product offerings in hospital business, leveraging existing distribution networks.
Capital allocation is more towards varied marketing expenditure to promote new products, especially in hospital and trade segments.
The transfer of API business to a wholly-owned subsidiary aims at enabling focused growth and capital efficiency but does not involve new capital expenditure.
Overall, growth strategy prioritizes variable marketing and R&D investments over fixed capital spending.

Track Themis Medicare — get its next earnings analysis in your feed

How does Themis Medicare rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

ThisThemis Medicare

Rev 2Mar 1

See where Themis Medicare sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

How does Themis Medicare rank in Pharmaceuticals & Biotechnology?

Compare Themis Medicare against every Pharmaceuticals & Biotechnology company (Q2 FY24) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

What Themis Medicare's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Remus Pharmaceuticals (Q2 FY27)
Standalone Revenue (H1 FY27 vs H1 FY26):** ₹62.08 Cr vs ₹46.85 Cr, growth of 32.51% . Key results statement takeaways from Remus Pharmaceuticals Ltd's Q2 FY27 e
Amrutanjan Healt (Q2 FY27)
Q2 FY27 Net Sales:** ₹135.18 Crores, up 14.85% YoY (₹117.70 Crores in Q2 FY26) . Key investor presentation takeaways from Amrutanjan Health Care Ltd's Q2 FY27 i
Pfizer (Q2 FY27)
Revenue from operations for the quarter ended September 30, 2026: ₹726.86 crore (Page 3). Key results statement takeaways from Pfizer Ltd's Q2 FY27 results stat
Aarti Drugs (Q2 FY27)
826.2 Crore, up 27% YoY from Rs. Key investor presentation takeaways from Aarti Drugs Ltd's Q2 FY27 investor presentation — and how it ranks against sector peer

Compare:vs Sun Pharmaceutical Industries vs Divis Laboratories vs Torrent Pharmaceuticals

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →